Etienne Garin, Jean-Baptiste Pinaquy, Clement Bailly, Christian Sengel, Denis Mariano-Goulart, Julien Edeline, Jean-Frederic Blanc, Antoine Bouvier, Jeremie Tordo, Agnes Rode, Stéphanie Becker, David Sefrioui, Thierry de Baere, Claude Somma, Charles Mastier, Jean Goupil, Patrick Chevallier, Helene Regnault, Eric Vibert, Sylvain Manfredi, Eric Vicaut, Binal Patel, Eveline Boucher, Boris Guiu
PRIMARY OBJECTIVE: Recently, selective internal radiation therapy using yttrium-90 (Y90) glass microspheres (TheraSphere™) was approved for reimbursement by health authorities in France. The PROACTIF study aims to gather data on effectiveness, patient quality of life, and safety with use of Y90 glass microspheres in real-world clinical settings in France. INCLUSION CRITERIA: Patient with a diagnosis of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCC), and/or metastatic colorectal cancer (mCRC) who was treated with a dose of Y90 glass microspheres that has been reimbursed in France and who do not oppose use of their personal medical data...
November 18, 2021: Cardiovascular and Interventional Radiology